<DOC>
	<DOCNO>NCT02756429</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) common cardiac arrhythmia . Because major impact general morbidity risk stroke , AF great concern public health . Several mechanism , include endothelial dysfunction inflammatory process , postulate predispose factor AF , well stroke . Both clinical experimental study highlight inflammation predispose factor AF complication . Nevertheless , source high inflammatory protein patient AF still unknown . We hypothesize multilevel intracardiac extracardiac ( left femoral vein , coronary sinus , leave atrium , pulmonary vein ) measurements several inflammatory protein ( VEGF ) would help assess extent source inflammation AF patient . The measurement von Willebrand factor ( vWF ) level multiple vascular site would also help define site endothelial dysfunction production thrombogenic factor . Although AF associate increase risk stroke , risk homogeneous . Permanent persistent AF associate similar thromboembolic risk paroxysmal AF .</brief_summary>
	<brief_title>Quantification Endothelial Thrombogenicity Patients With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Patient electrophysiology exploration ablation program ; Patient give write informed consent . Pregnant woman ; lung disease history ( source ) ; inflammatory disease history ( type ) ; Antiinflammatory treatment ; leave ventricular ejection fraction &lt; 35 % ; history stroke ; Participation ongoing clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>stroke</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>inflammation</keyword>
</DOC>